(Q30977943)

27 June 2017

1 reference

title

Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis (English)

1 reference

27 June 2017

0 references

Michael W Jann

1

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

24

1 reference

27 June 2017

issue

12

1 reference

27 June 2017

page(s)

1759-1783

1 reference

The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Recent advances in the neurobiology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The genetics of adult-onset neuropsychiatric disease: complexities and conundra?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Prefrontal neurons and the genetics of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Glutamate in schizophrenia: clinical and research implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate (Ant)agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Apolipoprotein D mRNA expression is elevated in PDAPP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Antipsychotic drugs differentially modulate apolipoprotein D in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The Fas signaling pathway: more than a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The mitochondrion: is it central to apoptosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Bcl-2 promotes regeneration of severed axons in mammalian CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Chronic elevation of brain-derived neurotrophic factor by ampakines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Signaling pathways for PC12 cell differentiation: making the right connections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+‐induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Atypical neuroleptics stimulate neurogenesis in adult rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Modern proteomic strategies in the study of complex neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Dopamine D1 receptors mediate CREB phosphorylation via phosphorylation of the NMDA receptor at Ser897-NR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Diverse psychotomimetics act through a common signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Communication in Neuronal Networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Chaos and schizophrenia: does the method fit the madness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Cognitive improvement in schizophrenia with novel antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Does cognitive function improve with quetiapine in comparison to haloperidol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

The architecture of cognitive control in the human prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Depression, III: treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Another view of therapy for cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.17.1759.52346

10.1592/PHCO.24.17.1759.52346

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference